Asco 2025 · Posters · Terapias en desarrollo · Javier Torres-Jiménez, MD Volver

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.

Abstract: 3028
Poster Bd #: 343
Descargar Poster

Javier Torres-Jiménez, MD

Hospital Universitario 12 de Octubre, Madrid

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo